NASDAQ
30.04.26 | 21:59
2,830 US-Dollar
+10,33 % +0,265
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.04. | Roche places a $1bn bet on C4T degrader-antibody conjugates | 9 | pharmaphorum | ||
| 10.04. | Roche and C4 Therapeutics to advance degrader-antibody conjugates research | 7 | Pharmaceutical Technology | ||
| 10.04. | Roche kehrt mit Degrader-Deal zu C4 Therapeutics zurück | 29 | transkript.de | ||
| 09.04. | C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies | 14 | Benzinga.com | ||
| 09.04. | C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates | 6 | Seeking Alpha | ||
| 09.04. | C4 Therapeutics Enters Collaboration Agreement With Roche | 430 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate... ► Artikel lesen | |
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.04. | Roche und C4 Therapeutics erweitern Forschungszusammenarbeit | 23 | cash | ||
| 09.04. | C4 Therapeutics, Roche partner on cancer degrader conjugates | 12 | Investing.com | ||
| 09.04. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma | 308 | GlobeNewswire (Europe) | WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 25.03. | Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock | 2 | Insider Monkey | ||
| 09.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 26.02. | Barclays raises C4 Therapeutics stock price target on trial progress | 9 | Investing.com | ||
| 26.02. | TD Cowen reiterates Buy rating on C4 Therapeutics stock | 1 | Investing.com | ||
| 26.02. | TD Cowen bestätigt "Buy"-Rating für C4 Therapeutics nach starkem Kursanstieg | 2 | Investing.com Deutsch | ||
| 26.02. | C4 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 26.02. | C4 Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 26.02. | C4 Therapeutics beats Q4 street views | 1 | Seeking Alpha | ||
| 26.02. | Earnings Summary: C4 Therapeutics Q4 | 1 | Benzinga.com | ||
| 26.02. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,468 | -0,68 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,951 | -0,89 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 27,500 | -1,86 % | Celldex Therapeutics, Inc.: Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease . | - Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,441 | -1,97 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| COHERUS ONCOLOGY | 1,516 | +0,20 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,630 | 0,00 % | Cathie Wood's ARK sells Nvidia stock, buys Arcturus Therapeutics | ||
| NEOVACS | 0,000 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.04.2026 | Das Instrument B4A1 CH0208062627 MEIER TOBLER GRP AG NAM. EQUITY wird cum Kapitalmassnahme gehandelt am 08.04.2026 und ex Kapitalmassnahme am 09.04.2026 The instrument B4A1 CH0208062627 MEIER TOBLER... ► Artikel lesen | |
| ULTRAGENYX | 21,160 | +0,57 % | Ultragenyx vor Quartalsbericht: Wichtiger Test für die Gentherapie-Pipeline | ||
| GYRE THERAPEUTICS | 6,500 | -0,76 % | Gyre Therapeutics Inc.: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 7,160 | +4,07 % | Morning Market Movers: Sagimet Biosciences, Compass Therapeutics, Oruka Therapeutics, Veradermics See Big Swings | SAN DIEGO (dpa-AFX) - At 8:00 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| GOSSAMER BIO | 0,303 | -3,19 % | Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension | - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 -
- At week... ► Artikel lesen | |
| BIOMEA FUSION | 1,365 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment | A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0-3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence... ► Artikel lesen | |
| JANUX THERAPEUTICS | 14,365 | +1,88 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| SOLID BIOSCIENCES | 7,260 | +3,20 % | Solid Biosciences receives EU orphan drug status for SGT-003 | ||
| TENAYA THERAPEUTICS | 0,699 | +5,40 % | Tenaya to present TN-401 gene therapy trial data at ASGCT |
Das Unternehmen C4 THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,265 (+10,33 %) liegt der Kurs bei 2,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.